Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Abreva Performance Claims Affirmed By NAD, Leave Novartis Sore

This article was originally published in The Tan Sheet

Executive Summary

Advertising claims that GlaxoSmithKline's cold-sore treatment Abreva "speeds healing like a prescription without one" are supported, the National Advertising Division of the Council of Better Business Bureaus concludes after a recent inquiry
Advertisement

Related Content

Merix/Glaxo Cold Sore Cold War Ends With Settlement
Merix/Glaxo Cold Sore Cold War Ends With Settlement
Merix/Glaxo Cold Sore Cold War Ends With Settlement
Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos
Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos

Topics

Advertisement
UsernamePublicRestriction

Register

PS096090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel